New drug shows promise for brain tumors from breast and lung cancer
NCT ID NCT05305365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called QBS72S in 21 adults with breast or lung cancer that has spread to the brain. The drug is given once a month through an IV. The main goal is to see if it shrinks brain tumors. The trial is active but not recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QBS72S (also called QBS10072S), a drug given by IV once a month
- What this could lead to
- If it works, this could point toward a new treatment option for people with cancer that has spread to the brain.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply widely. The drug may not shrink tumors or improve survival, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple